CD19 and B-cell chronic lymphocytic leukemia: In addition, Fraietta et al. [143] reported that out of the 41 patients with CLL who were treated with CD19-targeted CAR-T cells, those that achieved CR had a significantly lower percentage of CD8+ PD-1+ cells than the non-responders and those that achieved PR.